

Accepted Manuscript

Anti-Tumour Treatment

Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer

Jaume Capdevila, Kate Newbold, Lisa Licitra, Aron Popovtzer, Francesc Josep Moreso Mateo, José Zamorano, Michael Kreissl, Javier Aller, Enrique Grande

PII: S0305-7372(18)30113-0
DOI: <https://doi.org/10.1016/j.ctrv.2018.06.019>
Reference: YCTRV 1788

To appear in: *Cancer Treatment Reviews Cancer Treatment Reviews*

Received Date: 18 December 2017
Revised Date: 28 June 2018
Accepted Date: 29 June 2018

Please cite this article as: Capdevila, J., Newbold, K., Licitra, L., Popovtzer, A., Josep Moreso Mateo, F., Zamorano, J., Kreissl, M., Aller, J., Grande, E., Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer, *Cancer Treatment Reviews Cancer Treatment Reviews* (2018), doi: <https://doi.org/10.1016/j.ctrv.2018.06.019>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



OPTIMISATION OF TREATMENT WITH LENVATINIB IN RADIOACTIVE IODINE-REFRACTORY DIFFERENTIATED THYROID CANCER

Jaume Capdevila^{1*}MD Ph.D, Kate Newbold² Ph.D, Lisa Licitra³, Aron Popovtzer⁴, Francesc Josep Moreso Mateo⁵ MD Ph.D, José Zamorano⁶ Ph.D, Michael Kreissl⁷ MD, Javier Aller⁸ and Enrique Grande⁹ MD.

¹**Medical Oncology Department, Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron University Hospital, Barcelona, Spain.*

²*Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK.*

³*Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.*

⁴*Davidoff Cancer Center; Tel Aviv Medical School Sackler Israel.*

⁵*Renal Transplant Unit. Nephrology Department, Hospital Universitari Vall d'Hebron. Autonomous University of Barcelona. Barcelona. Spain*

⁶*Head of Cardiology, University Hospital Ramón y Cajal Madrid, Spain.*

⁷*Chief of the Department of Nuclear Medicine, Otto-von-Guericke-University/Medical Faculty Department of Radiology and Nuclear Medicine. Magdeburg, Germany.*

⁸*Endocrinology Department University Hospital Puerta de Hierro, Madrid, Spain.*

⁹*Medical Oncology Department, MD Anderson Cancer Center Madrid, Spain*

*Corresponding author:

Jaume Capdevila, MD, PhD Medical Oncology Department,

Gastrointestinal and Endocrine Tumor Unit,

Vall d'Hebron University Hospital,

Pg Vall d'Hebron, 119-129 08035 Barcelona,

Tel: 93 4894350- Fax: 93 2746781

jacapdevila@vhebron.net. jcapdevila@vhio.net.

Download English Version:

<https://daneshyari.com/en/article/8785795>

Download Persian Version:

<https://daneshyari.com/article/8785795>

[Daneshyari.com](https://daneshyari.com)